Want to see SE:BOUL full AI Analyst Report?
BOUL Stock Chart & Stats
kr2.49
-kr0.06(-2.35%)
―
--
Day’s Range― - ―
52-Week Rangekr2.46 - kr6.64
Previous CloseN/A
VolumeN/A
Average Volume (3M)39.82K
Market Cap
kr99.02M
Enterprise Valuekr351.77
Total Cash (Recent Filing)kr19.60M
Total Debt (Recent Filing)kr227.30M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Oct 23, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend Yield1.06%
Share Statistics
EPS (TTM)-0.10
Shares Outstanding38,833,103
10 Day Avg. Volume75,125
30 Day Avg. Volume39,822
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)1.11
Price to Sales (P/S)0.38
P/FCF Ratio-45.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)kr453.10M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueThe installed analyzer base can generate repeat consumables revenue over each instrument’s life, creating a more durable revenue stream than one-time equipment sales. This model can improve customer retention, support revenue visibility, and reinforce the value of Boule’s hematology platform.
Positive Cash GenerationPositive trailing-twelve-month operating and free cash flow show that the business is currently converting operations into cash despite a small net loss. That supports internal funding of operations and provides a stronger base for recovery, although consistency still needs to improve.
Improved Operating ProfitabilityThe return to positive operating profit indicates meaningful recovery from the 2024 loss, while relatively steady gross margins suggest core product economics remain intact. If maintained, this combination could support stronger earnings conversion as revenue stabilizes.
Bears Say
Declining RevenueOngoing top-line contraction remains a fundamental weakness because it limits operating leverage and makes recovery dependent on renewed demand or successful execution. Even though the decline is less severe than in 2024, sustained revenue pressure can constrain investment and earnings growth.
Higher Financial LeverageThe sharp increase in debt relative to equity reduces financial flexibility and leaves the company more exposed if earnings remain uneven. A higher debt burden can constrain capital allocation, increase financial risk, and make it harder to absorb further operating setbacks.
Unresolved Net LossesThe continued net loss shows that the operating recovery has not yet translated into sustainable bottom-line profitability. Until Boule consistently covers all costs below operating profit, its ability to strengthen equity, reduce leverage, and fund growth from earnings remains limited.
Boule Diagnostics AB News
BOUL FAQ
What was Boule Diagnostics AB’s price range in the past 12 months?
Boule Diagnostics AB lowest stock price was kr2.46 and its highest was kr6.64 in the past 12 months.
What is Boule Diagnostics AB’s market cap?
Boule Diagnostics AB’s market cap is kr99.02M.
When is Boule Diagnostics AB’s upcoming earnings report date?
Boule Diagnostics AB’s upcoming earnings report date is Oct 23, 2026 which is in 34 days.
How were Boule Diagnostics AB’s earnings last quarter?
Boule Diagnostics AB released its earnings results on Jul 17, 2026. The company reported -kr0.044 earnings per share for the quarter, missing the consensus estimate of kr0.01 by -kr0.054.
Is Boule Diagnostics AB overvalued?
According to Wall Street analysts Boule Diagnostics AB’s price is currently Undervalued.
Does Boule Diagnostics AB pay dividends?
Boule Diagnostics AB pays a Annually dividend of kr0.389 which represents an annual dividend yield of 1.06%. See more information on Boule Diagnostics AB dividends here
What is Boule Diagnostics AB’s EPS estimate?
Boule Diagnostics AB’s EPS estimate is -0.02.
How many shares outstanding does Boule Diagnostics AB have?
Boule Diagnostics AB has 38,833,103 shares outstanding.
What happened to Boule Diagnostics AB’s price movement after its last earnings report?
Boule Diagnostics AB reported an EPS of -kr0.044 in its last earnings report, missing expectations of kr0.01. Following the earnings report the stock price went down -8%.
Which hedge fund is a major shareholder of Boule Diagnostics AB?
Currently, no hedge funds are holding shares in SE:BOUL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.